Novel insight into the agonistic mechanism of alefacept in vivo: Differentially expressed genes may serve as biomarkers of response in psoriasis patients

Journal of Immunology

Volumn 178, Issue 11, 2007, Pages 7442-7449

  Haider, Asifa S ^a   Lowes, Michelle A ^a   Gardner, Humphrey ^b   Bandaru, Raj ^b   Darabi, Kamruz ^a   Chamian, Francesca ^a   Kikuchi, Toyoko ^a   Gilleaudeau, Patricia ^a   Whalen, Mary S ^a   Cardinale, Irma ^a   Novitskaya, Inna ^a   Krueger, James G ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

^b BIOGEN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEFACEPT; BIOLOGICAL MARKER; CD2 ANTIGEN; CD69 ANTIGEN; CYCLOSPORIN A; GAMMA INTERFERON; INTERLEUKIN 8; MESSENGER RNA; STAT1 PROTEIN; T LYMPHOCYTE RECEPTOR;

ADULT; AGED; APOPTOSIS; ARTICLE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CYTOLYSIS; DRUG MECHANISM; DRUG PROTEIN BINDING; FEMALE; GENE ACTIVATION; GENE EXPRESSION; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN CELL; INFLAMMATORY DISEASE; LEUKOCYTE ACTIVATION; MALE; NUCLEOTIDE SEQUENCE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PSORIASIS VULGARIS; RECEPTOR DOWN REGULATION; SKIN BIOPSY; T LYMPHOCYTE ACTIVATION;

EID: 34249826335     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.178.11.7442     Document Type: Article

References (26)

1. Lebwobl, M., S. K. Tyring, T. K. Hamilton, D. Toth, S. Glazer, N. H. Tawfik, P. Walicke, W. Dummer, X. Wang, M. R. Garovoy, and D. Pariser. 2003. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N. Engl. J. Med. 349: 2004-2013.
2. Ellis, C. N., and G. G. Krueger. 2001. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N. Engl. J. Med. 345: 248-255.
3. Sanders, M. E., M. W. Makgoba, S. O. Sharrow, D. Stephany, T. A. Springer, H. A., Young, and S. Shaw. 1988. Human memory T lymphocytes express increased levels of three cell adhesion molecules (LFA-3, CD2, and LFA-1) and three other molecules (UCHL1, CDw29, and Pgp-1) and have enhanced IFN-γ production. J. Immunol. 140: 1401-1407.
4. Bachmann, M. F., M. Barner, and M. Kopf. 1999. CD2 sets quantitative thresholds in T cell activation. J. Exp. Med. 190: 1383-1392.
5. Hunig, T., G. Tiefenthaler, K. H. Meyer zum Buschenfelde, and S. C. Meuer. 1987. Alternative pathway activation of T cells by binding of CD2 to its cell-surface ligand. Nature 326: 298-301.
6. + human T cells in vitro. Int. Immunol. 8: 1113-1119.
7. Bai, Y., S. Fu, S. Honig, Y. Wang, L. Qin, D. Chen, and J. S. Bromberg. 2002. CD2 is a dominant target for allogeneic responses. Am. J. Transplant. 2: 618-626.
8. Miller, G. T., P. S. Hochman, W. Meier, R. Tizard, S. A. Bixler, M. D. Rosa, and B. P. Wallner. 1993. Specific interaction of lymphocyte function-associated antigen 3 with CD2 can inhibit T cell responses, J. Exp. Med. 178: 211-222.
9. Ohno, H., T. Nakamura, H. Yagita, K. Okumura, M. Taniguchi, and T. Saito. 1991. Induction of negative signal through CD2 during antigen-specific T cell activation. J. Immunol. 147: 2100-2106.
10. + human T cells. Eur. J. Immunol. 33: 666-675.
11. Majeau, G. R., W. Meier, B. Jimmo, D. Kioussis, and P. S. Hochman. 1994. Mechanism of lymphocyte function-associated molecule 3-Ig fusion proteins inhibition of T cell responses: structure/function analysis in vitro and in human CD2 transgenic mice. J. Immunol. 152: 2753-2767.
12. Krueger, G. G. 2004. Current concepts and review of alefacept in the treatment of psoriasis. Dermatol. Clin. 22: 407-426, viii.
13. + T-cell-directed antibody responses are maintained in patients with psoriasis receiving alefacept: results of a randomized study. J. Am. Acad. Dermatol. 49: 816-825.
14. Chamian, F., M. A. Lowes, S. L. Lin, E. Lee, T. Kikuchi, P. Gilleaudeau, M. Sullivan-Whalen, I. Cardinale, A. Khatcherian, I. Novitskaya, et al. 2005. Alefacept reduces infiltrating T cells, activated dendritic cells, and inflammatory genes in psoriasis vulgaris. Proc. Natl. Acad. Sci. USA 102: 2075-2080.
15. Haider, A. S., S. B. Peters, H. Kaporis, I. Cardinale, J. Fei, J. Ott, M. Blumenberg, A.M. Bowcock, J. G. Krueger, and J. A. Carucci. 2006. Genomic analysis defines a cancer-specific gene expression signature for human squamous cell carcinoma and distinguishes malignant hyperproliferation from benign hyperplasia. J. Invest. Dermatol. 126: 869-881.
16. Lew, W., A. M. Bowcock, and J. G. Krueger. 2004. Psoriasis vulgaris: cutaneous lymphoid tissue supports T-cell activation and "type 1" inflammatory gene expression. Trends Immunol. 25: 295-305.
17. Lowes, M. A., F. Chamian, M. V. Abello, J. Fuentes-Duculan, S. L. Lin, R. Nussbaum, I. Novitskaya, H. Carbonaro, I. Cardinale, T. Kikuchi, et al. 2005. Increase in TNF-α and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a). Proc. Natl. Acad. Sci. USA 102: 19057-19062.
18. Gottlieb, A. B. 2004. Etanercept for the treatment of psoriasis and psoriatic arthritis. Dermatol. Ther. 17: 401-408.
19. Diehn, M., A. A. Alizadeh, O. J. Rando, C. L. Liu, K. Stankunas, D. Botstein, G. R. Crabtree, and P. O. Brown. 2002. Genomic expression programs and the integration of the CD28 costimulatory signal in T cell activation. Proc. Natl. Acad. Sci. USA 99: 11796-11801.
20. + T regulatory cells suppress autoimmunity while establishing transplantation tolerance. J. Immunol. 176: 7149-7153.
21. + cells. J. Immunol. 168: 4462-4471.
22. + T cells. J. Exp. Med. 197: 475-487.
23. Dusi, S., M. Donini, D. Lissandrini, P. Mazzi, V. D. Bianca, and F. Rossi. 2001. Mechanisms of expression of NADPH oxidase components in human cultured monocytes: role of cytokines and transcriptional regulators involved. Eur. J. Immunol. 31: 929-938.
24. Boruchov, A. M., G. Heller, M. C. Veri, E. Bonvini, J. V. Ravetch, and J. W. Young. 2005. Activating and inhibitory IgG Fc receptors on human DCs mediate opposing functions. J. Clin. Invest. 115: 2914-2923.
25. Krueger, G. G. 2003. Clinical response to alefacept: results of a phase 3 study of intravenous administration of alefacept in patients with chronic plaque psoriasis. J. Eur. Acad. Dermatol. Venereol. 17(Suppl. 2): 17-24.
26. Treon, S. P., M. Hansen, A. R. Branagan, S. Verselis, C. Emmanouilides, E. Kimby, S. R. Frankel, N. Touroutoglou, B. Turnbull, K. C. Anderson, et al. 2005. Polymorphisms in FcγRIIIA (CD 16) receptor expression are associated with clinical response to rituximab in Waldenstrom's macroglobulinemia. J. Clin. Oncol. 23: 474-481.